Idorsia Valuation
Is IDIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IDIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IDIA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IDIA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IDIA?
Other financial metrics that can be useful for relative valuation.
What is IDIA's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CHF 315.32m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 10.4x |
Enterprise Value/EBITDA | -3.9x |
PEG Ratio | -0.5x |
Price to Earnings Ratio vs Peers
How does IDIA's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 17.1x | ||
SANN Santhera Pharmaceuticals Holding | 2x | 32.5% | CHF 108.1m |
XLS Xlife Sciences | 10.3x | n/a | CHF 152.7m |
VYGR Voyager Therapeutics | 37x | -24.1% | US$334.3m |
COPN Cosmo Pharmaceuticals | 19.2x | -3.3% | CHF 1.2b |
IDIA Idorsia | 11x | -20.4% | CHF 315.3m |
Price-To-Earnings vs Peers: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the peer average (17.1x).
Price to Earnings Ratio vs Industry
How does IDIA's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the European Biotechs industry average (26.4x).
Price to Earnings Ratio vs Fair Ratio
What is IDIA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 11x |
Fair PE Ratio | 11.6x |
Price-To-Earnings vs Fair Ratio: IDIA is good value based on its Price-To-Earnings Ratio (11x) compared to the estimated Fair Price-To-Earnings Ratio (11.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 1.75 | CHF 1.78 +1.7% | 31.9% | CHF 2.60 | CHF 1.00 | n/a | 5 |
Sep ’25 | CHF 2.14 | CHF 1.78 -16.9% | 31.9% | CHF 2.60 | CHF 1.00 | n/a | 5 |
Aug ’25 | CHF 2.55 | CHF 1.76 -31.2% | 29.6% | CHF 2.60 | CHF 1.00 | n/a | 6 |
Jul ’25 | CHF 2.10 | CHF 1.69 -19.4% | 31.1% | CHF 2.60 | CHF 1.00 | n/a | 8 |
Jun ’25 | CHF 2.59 | CHF 1.69 -34.8% | 31.1% | CHF 2.60 | CHF 1.00 | n/a | 8 |
May ’25 | CHF 1.81 | CHF 1.72 -4.8% | 32.0% | CHF 2.60 | CHF 1.00 | n/a | 8 |
Apr ’25 | CHF 2.83 | CHF 2.10 -25.8% | 41.1% | CHF 4.00 | CHF 1.00 | n/a | 8 |
Mar ’25 | CHF 1.99 | CHF 2.07 +3.8% | 41.7% | CHF 4.00 | CHF 1.00 | n/a | 8 |
Feb ’25 | CHF 1.47 | CHF 2.07 +40.9% | 41.7% | CHF 4.00 | CHF 1.00 | n/a | 8 |
Jan ’25 | CHF 2.11 | CHF 2.07 -2.2% | 41.7% | CHF 4.00 | CHF 1.00 | n/a | 8 |
Dec ’24 | CHF 2.18 | CHF 2.63 +20.6% | 64.5% | CHF 6.50 | CHF 1.00 | n/a | 8 |
Nov ’24 | CHF 1.70 | CHF 4.24 +149.0% | 79.2% | CHF 12.00 | CHF 1.00 | n/a | 8 |
Oct ’24 | CHF 2.59 | CHF 6.38 +146.1% | 36.3% | CHF 12.00 | CHF 4.00 | n/a | 8 |
Sep ’24 | CHF 5.24 | CHF 6.28 +19.9% | 35.1% | CHF 12.00 | CHF 4.00 | CHF 2.14 | 9 |
Aug ’24 | CHF 6.90 | CHF 5.79 -16.1% | 13.1% | CHF 6.50 | CHF 4.20 | CHF 2.55 | 7 |
Jul ’24 | CHF 6.45 | CHF 10.91 +69.1% | 62.8% | CHF 30.00 | CHF 6.00 | CHF 2.10 | 10 |
Jun ’24 | CHF 7.99 | CHF 13.72 +71.8% | 57.0% | CHF 30.00 | CHF 7.00 | CHF 2.59 | 9 |
May ’24 | CHF 8.59 | CHF 13.46 +56.7% | 56.6% | CHF 30.00 | CHF 6.00 | CHF 1.81 | 10 |
Apr ’24 | CHF 10.02 | CHF 15.23 +52.0% | 39.7% | CHF 30.00 | CHF 9.00 | CHF 2.83 | 11 |
Mar ’24 | CHF 12.70 | CHF 15.23 +20.0% | 39.7% | CHF 30.00 | CHF 9.00 | CHF 1.99 | 11 |
Feb ’24 | CHF 15.18 | CHF 17.43 +14.8% | 39.2% | CHF 36.00 | CHF 10.00 | CHF 1.47 | 11 |
Jan ’24 | CHF 13.42 | CHF 18.17 +35.4% | 39.1% | CHF 36.00 | CHF 10.00 | CHF 2.11 | 11 |
Dec ’23 | CHF 14.36 | CHF 19.65 +36.9% | 35.0% | CHF 36.00 | CHF 10.00 | CHF 2.18 | 11 |
Nov ’23 | CHF 16.23 | CHF 19.71 +21.4% | 34.8% | CHF 36.00 | CHF 10.00 | CHF 1.70 | 10 |
Oct ’23 | CHF 12.86 | CHF 22.91 +78.2% | 33.2% | CHF 36.00 | CHF 10.00 | CHF 2.59 | 10 |
Sep ’23 | CHF 14.36 | CHF 24.92 +73.6% | 25.4% | CHF 36.00 | CHF 15.00 | CHF 5.24 | 11 |
Analyst Forecast: Target price is less than 20% higher than the current share price.